Victor Golmer/iStock Editorial via Getty Images The markets weren't happy with the recent second quarter (Q2 2024) results of the Danish pharmaceuticals company Novo Nordisk’s (NVO), of Ozempic fame. The stock tanked 8.4% on the day, and while it has recovered since, the sharp initial reaction is intriguing enough to call for a closer look at the numbers. Wegovy drives price decline... Initial investor disappointment is attributed to a cooling off in the company's highly successful treatment, Wegovy's s ...